Schilke Tobin
Schilke Tobin, CF, IO, reported a transaction classified as grant at Crinetics Pharmaceuticals, Inc. involving 471.000000 shares for an estimated $0.00. Reported holdings after the transaction were 79427.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
- Trade date
- Aug 20, 2026
- Filing date
- Aug 24, 2026
How reported position traded is calculated
Calculated only for code-P purchases and code-S sales.
Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.
CRNX price since this filing
Daily closing prices, with the filing date and available return windowsTransaction facts
Stored Form 4 columns with their raw values
- Type
- grant Code A
- Identifier
- 0001628280-26-058664 Common Stock
- Transaction date
- Aug 20, 2026 Filed Aug 24, 2026, 08:52 PM · 4d delay
- Shares
- 471 sh $0.00 per share
- Estimated value
- $0 Computed from shares × price
- Holdings after
- 79,427 sh Direct
Filing signal explanations
Badges describe filing facts only — not predictions.
-16 points
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
How this score is calculated
- direct_ownership+6 points
direct_or_indirect_ownership = D
Direct ownership reports the insider's personal stake. - grant_or_award-22 points
transaction_code = A
Grant or award transactions are scheduled compensation, not discretionary.
Signed filing-only points, not a probability or expected return. Version v1.
Reported relationships & other filings
Form 4 relationship flags and nearby filing context
Chief Financial & Infra. Ofcr.
- F1
The transaction reported on this line involves the receipt of restricted stock units, which represent the right to receive shares of the Issuer's Common Stock, with 25% vesting annually beginning on S…
- F2
Includes 835 shares acquired under the Issuer's Employee Stock Purchase Plan.
0 other transactions
0 recent txs